These results, taken together, indicate that the toxicity of PARIS in PD models might be attributable not only to transcriptional suppression of PGC-1α, but also to the inhibition of PGC-1α by MYBBP1A upregulation and p53 activation. This evidence concerns the gene TP53 and Parkinson disease.